February 2022

Contents

Editorial

• HTB: no. 1/2 (January/February 2022)

• i-Base appeal: please support i-Base with £5 or £10 a month

Conference reports

• CROI 2022 to only be virtual: programme online

Antiretrovirals

• US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir/rilpivirine

• Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent

Guidelines

• BHIVA interim guidance on long-acting cabotegravir and rilpivirine injections

Coinfections and complications

• HIV-associated reductions in telomere length are stopped by effective ART

Resistance

• Drug resistance profile of integrase inhibitors when treating HIV-2

Other news

• EACS HIV Summer School 2022: Applications are open

COVID-19: investigational drugs

• UK RECOVERY study shows no benefit from aspirin in people hospitalised with COVID-19

COVID-19: guidelines

• IDSA update COVID-19 guidelines (January 2022)

Job vacancies

• i-Base vacancy: HIV treatment advocate and information officer

PDFs

• HTB: no. 1/2 – plus HIV and COVID-19 (7 February 2022)